Sign in →

Test Code CMAPT Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded

Reporting Name

Chromosomal Microarray, Tumor, FFPE

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Useful For

Genomic characterization of tumor for copy number imbalances and loss of heterozygosity

 

Assisting in the diagnosis and classification of malignant neoplasms

 

Evaluating the prognosis for patients with malignant tumors

Method Name

Chromosomal Microarray (CMA)


Ordering Guidance


This test is not performed on fresh tissue specimens. If testing is needed for fresh tissue specimens, order CMAT / Chromosomal Microarray, Tumor, Fresh or Frozen.

 

If a fresh tissue specimen is submitted, this test will be canceled and CMAT will be performed and charged.



Additional Testing Requirements


 



Necessary Information


A reason for testing and pathology report are required for testing to be performed. Send information with specimen. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.



Specimen Required


Submit only 1 of the following specimens:

 

Specimen Type: Tissue

Container/Tube: Formalin-fixed, paraffin-embedded tumor tissue block

 

Specimen Type: Slides

Specimen Volume: 10 Consecutive, unstained, 5-micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide


Specimen Type

Varies

Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Ambient (preferred)
  Refrigerated 

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Reference Values

An interpretive report will be provided.

Interpretation

The interpretive report describes copy number changes and any loss of heterozygosity that may be associated with the neoplastic process. Abnormal clones with subclonal cytogenetic evolution will be discussed if identified.

 

The continual discovery of novel copy number variation and published clinical reports means that the interpretation of any given copy number change may evolve with increased scientific understanding.

 

Although the presence of a clonal abnormality usually indicates a neoplasia, in some situations it may reflect a benign or constitutional genetic change. If a genetic change is identified that is likely constitutional and clearly disease-associated (eg, XYY), follow-up with a medical genetic consultation may be suggested.

 

The absence of an abnormal clone may be the result of specimen collection from a site that is not involved in the neoplasm or may indicate that the disorder is caused by a point mutation that is not detectable by chromosomal microarray.

 

Chromosomal microarray, fluorescence in situ hybridization (FISH), and conventional cytogenetics are to some extent complementary methods. In some instances, additional FISH or conventional cytogenetic studies will be recommended to clarify interpretive uncertainties.

 

For more information and frequently asked questions, see Clarity on Reason for and Benefits of Chromosomal Microarray.

Day(s) Performed

Monday through Friday

Report Available

10 to 21 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81277

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CMAPT Chromosomal Microarray, Tumor, FFPE 94087-4

 

Result ID Test Result Name Result LOINC Value
54735 Result Summary 50397-9
54736 Result 62356-1
54737 Nomenclature 62378-5
54738 Interpretation 69965-2
CG908 Reason for Referral 42349-1
54744 Specimen 31208-2
54739 Source 31208-2
54740 Tissue ID 80398-1
54741 Method 85069-3
53425 Additional Information 48767-8
54742 Released By 18771-6

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Testing Algorithm

This test does not include a pathology consult. If a pathology consultation is requested, PATHC / Pathology Consultation should be ordered, and the appropriate fluorescence in situ hybridization (FISH) test will be ordered and performed at an additional charge.

 

Hematoxylin and eosin stain review of the paraffin-embedded sample is performed to identify the area of invasive tumor prior to DNA extraction and microarray analysis. If additional FISH testing is requested, it will be performed at an additional charge.

 

For more information see Aggressive B-cell Lymphoma Diagnostic Algorithm.